Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03797261
Recruitment Status : Recruiting
First Posted : January 9, 2019
Last Update Posted : May 17, 2019
Sponsor:
Collaborators:
Genentech, Inc.
Amgen
Information provided by (Responsible Party):
AbbVie

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 2, 2022
  Estimated Study Completion Date : September 2, 2022